Modality
Peptide
MOA
CFTRmod
Target
GLP-1R
Pathway
Ferroptosis
FTD
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Jul 2028
Phase 2Current
NCT08905725
1,840 pts·FTD
2018-12→2028-07·Recruiting
1,840 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-102.3y awayPh3 Readout· FTD
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2028-07-10 · 2.3y away
FTD
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08905725 | Phase 2/3 | FTD | Recruiting | 1840 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R |